To describe the journey of patients with metastatic castration-resistant prostate cancer (mCRPC) in treatment with radium-223.
A multiperspective analysis was performed using narrative medicine in four Italian centers.
The substantial impact of mCRPC on quality of life through all phases of the disease was described. After an initial lack of awareness of the disease or denial of its effects, symptoms of pain, fatigue and side effects often led to sadness, fear and loneliness. The majority underwent radium-223 therapy positively, restoring their quality of life and routine activities.
Using narrative medicine, the importance of a patient-centered approach in the pathway of care for patients with mCRPC through all the stages of the disease was highlighted.
Future oncology (London, England). 2018 Jun 15 [Epub ahead of print]
Giuseppe De Vincentis, Fabio Monari, Sergio Baldari, Matteo Salgarello, Viviana Frantellizzi, Elisabetta Salvi, Luigi Reale, Silvia Napolitano, Giario Conti, Enrico Cortesi
Department of Radiological Sciences, Oncology & Anatomo-Pathology, Sapienza - University of Rome, Rome, Italy., UO Metabolic Radiation Unit Bologna, Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola-Malpighi, Emilia-Romagna, Italy., Department of Biomedical Sciences & Morphological & Functional Images, Università degli Studi di Messina, Messina, Italy., Division of Nuclear Medicine, Sacro Cuore - Don Calabria Hospital, Negraro (VR), Italy., ISTUD Foundation, Healthcare Area, Milan, Italy., Department of Urology, Sant'Anna Hospital, Como, Italy., Medical Oncology, Policlinico Umberto I, Sapienza, University of Rome, Rome, Italy.